Literature DB >> 9340414

[Tissue plasminogen activator in treatment of fibrinous membranes after cataract surgery].

J Oficjalska-Młyńczak1, J Marek, H Zajac-Pytrus, M H Nizankowska, M Koziorowska.   

Abstract

UNLABELLED: The aim of our study is estimation of the efficacy of recombinant tissue plasminogen activator for the treatment of fibrinous membranes following cataract extraction. PATIENTS AND METHODS: The fibrinous membranes were formed, despite conventional antiinflammatory therapy, in 17 eyes after ECCE with IOL and in 3 eyes after ECCE without IOL. We injected the solution of recombinant tissue plasminogen activator-Actilyse (Boehringer Ingelheim) into the anterior chamber of 20 eyes after cataract surgery. Simultaneously, topical corticosteroid and cycloplegic therapy was continued. Routine follow-up included slit lamp examination, ophthalmoscopy and intraocular pressure measurement.
RESULTS: Injection of the solution of tissue plasminogen activator into anterior chamber of 20 eyes resulted in complete dissolution of the fibrinous membranes in 18 eyes within 1 day. In 7 eyes, within a few days after injection, fibrinous membrane recurred. In four of this cases durable effect of fibrin dissolution was obtained after multiple tPA injections. Finally, expectable stable result was obtained in 15 of 20 eyes.
CONCLUSIONS: Results of our study confirm high efficacy of recombinant tissue plasminogen activator in the treatment of fibrinous membranes after cataract surgery. Short term follow-up and small number of cases motivates further continuation of observation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9340414

Source DB:  PubMed          Journal:  Klin Oczna        ISSN: 0023-2157


  1 in total

1.  Enzymatic vitreolysis with recombinant tissue plasminogen activator for vitreomacular traction.

Authors:  Dorota Raczyńska; Paweł Lipowski; Katarzyna Zorena; Andrzej Skorek; Paulina Glasner
Journal:  Drug Des Devel Ther       Date:  2015-11-27       Impact factor: 4.162

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.